{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:58:14Z","timestamp":1789441094737,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.aed.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:07:58Z","timestamp":1747368478000},"page":"107-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab-Induced Thyroid Storm in a Patient With Triple-Negative Breast Cancer"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7924-7624","authenticated-orcid":false,"given":"Sobrina S.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Asad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shourya","family":"Tadisina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.aed.2025.04.008_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3803\/EnM.2020.906","article-title":"Characteristics of immune-related thyroid adverse events in patients treated with PD-1\/PD-L1 inhibitors","volume":"36","author":"Yoon","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.aed.2025.04.008_bib2","article-title":"A case report of Graves\u2019 disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient","volume":"2019","author":"Yajima","year":"2019","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.aed.2025.04.008_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.aed.2025.04.008_bib4","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aed.2025.04.008_bib5","article-title":"A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis","volume":"2015","author":"Yu","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"1","key":"10.1016\/j.aed.2025.04.008_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13256-018-1708-x","article-title":"Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto\u2019s disease and diabetes mellitus: a case report","volume":"12","author":"Yonezaki","year":"2018","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.aed.2025.04.008_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1530-891X(20)39607-5","article-title":"Abstract #805063: thyroid storm resulting from an acute onset Hashimoto\u2019s thyroiditis in a patient with history of metastatic nonsmall cell lung cancer treated with Pembrolizumab","volume":"26","author":"Ahmad","year":"2020","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.aed.2025.04.008_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0889-8529(18)30165-8","article-title":"Life-threatening thyrotoxicosis. Thyroid storm","volume":"22","author":"Burch","year":"1993","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"12","key":"10.1016\/j.aed.2025.04.008_bib9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1507\/endocrj.EJ16-0336","article-title":"2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First Edition)","volume":"63","author":"Satoh","year":"2016","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.aed.2025.04.008_bib10","first-page":"199","article-title":"Pembrolizumab-induced thyroid storm","volume":"38","author":"Niedzialkowska","year":"2025","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"10","key":"10.1016\/j.aed.2025.04.008_bib11","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect"},{"issue":"4","key":"10.1016\/j.aed.2025.04.008_bib12","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","article-title":"Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients","volume":"48","author":"Campredon","year":"2019","journal-title":"Presse Med"},{"issue":"6","key":"10.1016\/j.aed.2025.04.008_bib13","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3390\/cancers13061464","article-title":"Thyroid dysfunction in lung cancer patients treated with immune checkpoint inhibitors (ICIs): outcomes in a multiethnic urban cohort","volume":"13","author":"D\u2019Aiello","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.aed.2025.04.008_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"issue":"10","key":"10.1016\/j.aed.2025.04.008_bib15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1507\/endocrj.EJ19-0234","article-title":"Comprehensive research on thyroid diseases associated with autoimmunity: autoimmune thyroid diseases, thyroid diseases during immune-checkpoint inhibitors therapy, and immunoglobulin-G4-associated thyroid diseases","volume":"66","author":"Inaba","year":"2019","journal-title":"Endocr J"},{"issue":"10","key":"10.1016\/j.aed.2025.04.008_bib16","doi-asserted-by":"crossref","first-page":"e3620","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.aed.2025.04.008_bib17","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s40618-023-02096-2","article-title":"Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center","volume":"46","author":"Ruggeri","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.aed.2025.04.008_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2478\/jtim-2022-0009","article-title":"Immune checkpoint inhibitor-related endocrinopathies","volume":"10","author":"Lu","year":"2022","journal-title":"J Transl Int Med"},{"issue":"15_suppl","key":"10.1016\/j.aed.2025.04.008_bib19","doi-asserted-by":"crossref","first-page":"e15160","DOI":"10.1200\/JCO.2020.38.15_suppl.e15160","article-title":"Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors","volume":"38","author":"Qin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.aed.2025.04.008_bib20","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1093\/oncolo\/oyab043","article-title":"Immune checkpoint inhibitor-related new-onset thyroid dysfunction: a retrospective analysis using the US FDA Adverse Event Reporting System","volume":"27","author":"Lu","year":"2022","journal-title":"Oncologist"},{"issue":"36","key":"10.1016\/j.aed.2025.04.008_bib21","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305091572500027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305091572500027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:16:28Z","timestamp":1768569388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305091572500027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S305091572500027X"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2025.04.008","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-Induced Thyroid Storm in a Patient With Triple-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Association of Clinical Endocrinologists. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}